Study finds Novo Nordisk diabetes drug works better than original
NEW ORLEANS Results of a phase 3 study presented Sunday at the American Diabetes Association’s 69th annual scientific sessions indicates that an investigational diabetes drug works better than a drug originally made by Sanofi-Aventis.
Danish drug maker Novo Nordisk presented data showing that liraglutide was more effective at lowering blood sugar when taken alone than glimepiride, which Sanofi originally marketed under the name Amaryl and is now available as a generic.
In the study, 58% of patients who took 1.8 mg doses of the once-daily drug reached the ADA’s blood sugar target of less than 7%, compared with 37% of patients who took 8 mg of glimepiride once a day.
“The fact that liraglutide continues to effectively lower blood sugar after two years of treatment is consistent with its other long-term clinical benefits such as continued reductions in fasting blood sugar and weight,” lead investigator and Baylor College of Medicine researcher Alan Garber said in a statement. “Even with available treatments, many Type 2 diabetes patients still struggle to control their blood sugar, while losing weight.”
Innovative Card Scanning teams up with RediClinic
PLANO, Texas Innovative Card Scanning, a developer and provider of insurance card and ID scanning solutions for physicians, hospitals, medical billers, pharmacies and retail clinics, has teamed up with RediClinic.
Innovative Card Scanning’s DocketPORT Scanning Technology is now in place at 21 RediClinic locations across Houston and Austin, with plans for the scanning technology to be placed in future locations.
“Our business is based around the treatment of common conditions that can be accomplished conveniently and quickly for patients. It’s very important for us to optimize our check-in process to be as quick and efficient as we can, and this is one more way to help make that a reality,” stated RediClinic COO Lori Knowles.
With the new system, RediClinic patients have their insurance card and/ or driver’s license immediately scanned upon the office visit, creating a secure electronic record that follows them throughout the billing process.
The RediClinic billing department uses these files as a reference throughout the process to quickly confirm information accuracy or identify and correct any errors in-house. This system eliminates the need for paper files or to perform outside research to correct errors, and saves payment and claims that would sometimes be lost due to insufficient contact information, according to the company.
RedicClinic will have the option to further upgrade to Innovative Card Scanning’s optical character recognition technology, which will automatically extract patient data and populate it into their EMR system.
Merck: Investigational drug did not meet endpoints
WHITEHOUSE STATION, N.J. Merck & Co. said Friday that preliminary results for the pivotal phase III study of rolofylline (MK-7418), the company’s investigational medicine for the treatment of acute heart failure, show that rolofylline did not meet the primary or secondary efficacy endpoints.
“Advances to help patients with acute heart failure, a disease that is the leading cause of hospitalization for patients over age 65 and that is associated with a high rate of mortality, have long been elusive,” said Dan Bloomfield, M.D., executive director, cardiovascular research, Merck Research Laboratories. “These results are disappointing because we had been hopeful that blocking the adenosine A1 receptor with rolofylline would prove to be a useful new approach for these patients.
The primary endpoint for the phase III study were that the drug would would improve symptoms of acute heart failure (compared with placebo). Secondary endpoints included reducing the risk of death, renal re-hospitalization 60 days after treatment and reducing the incidence of persistent kidney impairment.
Rolofylline was acquired by Merck through NovaCardia, which Merck purchased in 2007. Results from the PROTECT pilot study, presented at previous medical meetings and published in 2008, had showed an overall trend toward efficacy (more patients with improved shortness of breath, fewer patients with worsening renal function and/or worsening heart failure).
While Merck will continue to analyze the data with outside experts, the company will not file applications for regulatory approval this year. The results from this study will be presented at a medical meeting later this year.
Merck’s late-stage pipeline of investigational medicines for cardiovascular disease includes MK-524A (approved in some markets outside the U.S.), MK-524B, ezetimibe/atorvastatin, and anacetrapib (MK-0859) for atherosclerosis, and vernakalant for atrial fibrillation.